Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

Martina Sattlecker; Steven J Kiddle; Stephen Newhouse; Petroula Proitsi; Sally Nelson; Stephen Williams; Caroline Johnston; Richard Killick; Andrew Simmons; Eric Westman; Angela Hodges; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Simon Lovestone; the AddNeuroMed Consortium; Richard J B Dobson

doi:10.1016/j.jalz.2013.09.016

Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

Martina Sattlecker, Steven J Kiddle, Stephen Newhouse, Petroula Proitsi, Sally Nelson, Stephen Williams, Caroline Johnston, Richard Killick, Andrew Simmons, Eric Westman, Angela Hodges, Hilkka Soininen, Iwona Kłoszewska, Patrizia Mecocci, Magda Tsolaki, Bruno Vellas, Simon Lovestone, the AddNeuroMed Consortium, Richard J B Dobson

Research output: Contribution to journal › Article › peer-review

163 Citations (Scopus)

161 Downloads (Pure)

Abstract

Blood proteins and their complexes have become the focus of a great deal of interest in the context of their potential as biomarkers of Alzheimer's disease (AD). We used a SOMAscan assay for quantifying 1001 proteins in blood samples from 331 AD, 211 controls, and 149 mild cognitive impaired (MCI) subjects. The strongest associations of protein levels with AD outcomes were prostate-specific antigen complexed to α1-antichymotrypsin (AD diagnosis), pancreatic prohormone (AD diagnosis, left entorhinal cortex atrophy, and left hippocampus atrophy), clusterin (rate of cognitive decline), and fetuin B (left entorhinal atrophy). Multivariate analysis found that a subset of 13 proteins predicted AD with an accuracy of area under the curve of 0.70. Our replication of previous findings provides further evidence that levels of these proteins in plasma are truly associated with AD. The newly identified proteins could be potential biomarkers and are worthy of further investigation.

Original language	English
Pages (from-to)	724-734
Number of pages	11
Journal	Alzheimer's & Dementia
Volume	10
Issue number	6
Early online date	28 Apr 2014
DOIs	https://doi.org/10.1016/j.jalz.2013.09.016
Publication status	Published - 28 Apr 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jalz.2013.09.016Licence: CC BY-NC-ND

Alzheimer's disease biomarker discovery_DOBSON_Published28April2018_GOLD VoR (CC BY NC ND)Final published version, 1.34 MBLicence: CC BY-NC-ND

Cite this

Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., Hodges, A., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., the AddNeuroMed Consortium, & Dobson, R. J. B. (2014). Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's & Dementia, 10(6), 724-734. https://doi.org/10.1016/j.jalz.2013.09.016

@article{ec0dd2bfcf95470d8ee924d9f0160f61,

title = "Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology",

abstract = "Blood proteins and their complexes have become the focus of a great deal of interest in the context of their potential as biomarkers of Alzheimer's disease (AD). We used a SOMAscan assay for quantifying 1001 proteins in blood samples from 331 AD, 211 controls, and 149 mild cognitive impaired (MCI) subjects. The strongest associations of protein levels with AD outcomes were prostate-specific antigen complexed to α1-antichymotrypsin (AD diagnosis), pancreatic prohormone (AD diagnosis, left entorhinal cortex atrophy, and left hippocampus atrophy), clusterin (rate of cognitive decline), and fetuin B (left entorhinal atrophy). Multivariate analysis found that a subset of 13 proteins predicted AD with an accuracy of area under the curve of 0.70. Our replication of previous findings provides further evidence that levels of these proteins in plasma are truly associated with AD. The newly identified proteins could be potential biomarkers and are worthy of further investigation.",

author = "Martina Sattlecker and Kiddle, {Steven J} and Stephen Newhouse and Petroula Proitsi and Sally Nelson and Stephen Williams and Caroline Johnston and Richard Killick and Andrew Simmons and Eric Westman and Angela Hodges and Hilkka Soininen and Iwona K{\l}oszewska and Patrizia Mecocci and Magda Tsolaki and Bruno Vellas and Simon Lovestone and {the AddNeuroMed Consortium} and Dobson, {Richard J B}",

year = "2014",

month = apr,

day = "28",

doi = "10.1016/j.jalz.2013.09.016",

language = "English",

volume = "10",

pages = "724--734",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

number = "6",

}

Sattlecker, M , Kiddle, SJ , Newhouse, S , Proitsi, P, Nelson, S, Williams, S, Johnston, C, Killick, R , Simmons, A, Westman, E, Hodges, A, Soininen, H, Kłoszewska, I, Mecocci, P, Tsolaki, M, Vellas, B, Lovestone, S, the AddNeuroMed Consortium & Dobson, RJB 2014, 'Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology', Alzheimer's & Dementia, vol. 10, no. 6, pp. 724-734. https://doi.org/10.1016/j.jalz.2013.09.016

TY - JOUR

T1 - Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

AU - Sattlecker, Martina

AU - Kiddle, Steven J

AU - Newhouse, Stephen

AU - Proitsi, Petroula

AU - Nelson, Sally

AU - Williams, Stephen

AU - Johnston, Caroline

AU - Killick, Richard

AU - Simmons, Andrew

AU - Westman, Eric

AU - Hodges, Angela

AU - Soininen, Hilkka

AU - Kłoszewska, Iwona

AU - Mecocci, Patrizia

AU - Tsolaki, Magda

AU - Vellas, Bruno

AU - Lovestone, Simon

AU - the AddNeuroMed Consortium

AU - Dobson, Richard J B

PY - 2014/4/28

Y1 - 2014/4/28

N2 - Blood proteins and their complexes have become the focus of a great deal of interest in the context of their potential as biomarkers of Alzheimer's disease (AD). We used a SOMAscan assay for quantifying 1001 proteins in blood samples from 331 AD, 211 controls, and 149 mild cognitive impaired (MCI) subjects. The strongest associations of protein levels with AD outcomes were prostate-specific antigen complexed to α1-antichymotrypsin (AD diagnosis), pancreatic prohormone (AD diagnosis, left entorhinal cortex atrophy, and left hippocampus atrophy), clusterin (rate of cognitive decline), and fetuin B (left entorhinal atrophy). Multivariate analysis found that a subset of 13 proteins predicted AD with an accuracy of area under the curve of 0.70. Our replication of previous findings provides further evidence that levels of these proteins in plasma are truly associated with AD. The newly identified proteins could be potential biomarkers and are worthy of further investigation.

AB - Blood proteins and their complexes have become the focus of a great deal of interest in the context of their potential as biomarkers of Alzheimer's disease (AD). We used a SOMAscan assay for quantifying 1001 proteins in blood samples from 331 AD, 211 controls, and 149 mild cognitive impaired (MCI) subjects. The strongest associations of protein levels with AD outcomes were prostate-specific antigen complexed to α1-antichymotrypsin (AD diagnosis), pancreatic prohormone (AD diagnosis, left entorhinal cortex atrophy, and left hippocampus atrophy), clusterin (rate of cognitive decline), and fetuin B (left entorhinal atrophy). Multivariate analysis found that a subset of 13 proteins predicted AD with an accuracy of area under the curve of 0.70. Our replication of previous findings provides further evidence that levels of these proteins in plasma are truly associated with AD. The newly identified proteins could be potential biomarkers and are worthy of further investigation.

U2 - 10.1016/j.jalz.2013.09.016

DO - 10.1016/j.jalz.2013.09.016

M3 - Article

C2 - 24768341

SN - 1552-5260

VL - 10

SP - 724

EP - 734

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 6

ER -

Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this